Therapeutic Advances in Women's Cancers

Front Biosci (Schol Ed). 2011 Jan 1;3:82-97. doi: 10.2741/s134.

Abstract

Cytotoxic therapy and surgery have improved outcomes for patients with gynecologic malignancies over the last twenty years, but women's cancers still account for over ten percent of cancer related deaths annually. Insights into the pathogenesis of cancer have led to the development of drugs that target molecular pathways essential to tumor survival including angiogenesis, DNA repair, and apoptosis. This review outlines several of the promising new biologically targeted drugs currently being tested to treat gynecologic malignancies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates / pharmacology
  • Bevacizumab
  • Cetuximab
  • ErbB Receptors / metabolism
  • Female
  • Genital Neoplasms, Female / drug therapy*
  • Genital Neoplasms, Female / therapy*
  • Humans
  • Indoles / pharmacology
  • Intestinal Perforation / chemically induced
  • Neovascularization, Pathologic / drug therapy*
  • Niacinamide / analogs & derivatives
  • PTEN Phosphohydrolase / metabolism
  • Phenylurea Compounds
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyridines / pharmacology
  • Pyrroles / pharmacology
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor / metabolism
  • Sorafenib
  • Sunitinib
  • TOR Serine-Threonine Kinases / metabolism
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Pyridines
  • Pyrroles
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Bevacizumab
  • Sorafenib
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • EGFR protein, human
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Cetuximab
  • Sunitinib